Global Leukemia Therapeutics Market Analysis - 2019-2028
Leukemia therapeutics are effective drugs & biologics capable of generating a therapeutic effect on a leukemia patient by slowing down the growth or killing the cancer cells. The global leukemia therapeutics market is anticipated to achieve a CAGR of 10.81% across the globe over the forecast period, 2021-2028. Factors such as the continuous advancements and development for blood cancer testing, increasing number of patients with leukemia, which is raising the need for advanced treatment solutions, increasing R & D investments and the growing advancements in technology in the healthcare sector are anticipated to promote towards the growth of the global leukemia therapeutics market. Additionally, factors such as the growing concern for leukemia, which is also raising the need for the effective treatment of the disease, is anticipated to drive the growth of the global leukemia therapeutics market.
The global leukemia therapeutics market consists of various segments that are segmented by application, drug class, route of administration, therapy, end user and by region. The market is further segmented by application into acute lymphocytic leukemia, chronic lymphocytic leukemia, acute myeloid leukemia, chronic myeloid leukemia and others. Out of these, the chronic lymphocytic leukemia segment is anticipated to register the largest market share by growing at a CAGR of around 10% during the forecast period. Chronic Lymphocytic Leukemia is the most common type of leukemia in adults in the world's Western part. According to the American Cancer Society, Chronic Lymphocytic Leukemia accounts for approximately one-quarter of leukemia cases. According to the National Cancer Institute, about 186,422 people were suffering from CLL in the US, in the year 2017.
Based on region, the global leukemia therapeutics market is segmented into five major regions including North America, Latin America, Europe, Asia Pacific, Middle East and Africa. The market in Europe registered a significant market share of around 29% in the year 2019 and is primarily driven by nations such as the UK, Germany, France, Italy and others. The market in Europe is further anticipated to gain an incremental $ opportunity of around USD 328.39 million in the year 2020 as compared to the previous year.
Some of the affluent industry leaders in the global leukemia therapeutics market are Amgen Inc., F. Hoffmann-La Roche Ltd., AstraZeneca Plc., Novartis AG, AbbVie Inc., Sanofi and Gilead Sciences.
Leukemia therapeutics are effective drugs & biologics capable of generating a therapeutic effect on a leukemia patient by slowing down the growth or killing the cancer cells. The global leukemia therapeutics market is anticipated to achieve a CAGR of 10.81% across the globe over the forecast period, 2021-2028. Factors such as the continuous advancements and development for blood cancer testing, increasing number of patients with leukemia, which is raising the need for advanced treatment solutions, increasing R & D investments and the growing advancements in technology in the healthcare sector are anticipated to promote towards the growth of the global leukemia therapeutics market. Additionally, factors such as the growing concern for leukemia, which is also raising the need for the effective treatment of the disease, is anticipated to drive the growth of the global leukemia therapeutics market.
The global leukemia therapeutics market consists of various segments that are segmented by application, drug class, route of administration, therapy, end user and by region. The market is further segmented by application into acute lymphocytic leukemia, chronic lymphocytic leukemia, acute myeloid leukemia, chronic myeloid leukemia and others. Out of these, the chronic lymphocytic leukemia segment is anticipated to register the largest market share by growing at a CAGR of around 10% during the forecast period. Chronic Lymphocytic Leukemia is the most common type of leukemia in adults in the world's Western part. According to the American Cancer Society, Chronic Lymphocytic Leukemia accounts for approximately one-quarter of leukemia cases. According to the National Cancer Institute, about 186,422 people were suffering from CLL in the US, in the year 2017.
Based on region, the global leukemia therapeutics market is segmented into five major regions including North America, Latin America, Europe, Asia Pacific, Middle East and Africa. The market in Europe registered a significant market share of around 29% in the year 2019 and is primarily driven by nations such as the UK, Germany, France, Italy and others. The market in Europe is further anticipated to gain an incremental $ opportunity of around USD 328.39 million in the year 2020 as compared to the previous year.
Some of the affluent industry leaders in the global leukemia therapeutics market are Amgen Inc., F. Hoffmann-La Roche Ltd., AstraZeneca Plc., Novartis AG, AbbVie Inc., Sanofi and Gilead Sciences.
Table of Contents
Global Leukemia Therapeutics Market2. Assumptions and Acronyms3. Research Methodology4. Executive Summary- Global Leukemia Therapeutics Market5. Regulatory Landscape6. Epidemiology Analysis9. Evaluation on the Impact of COVID-19 on the Global Leukemia Therapeutics Market12. Strategic Recommendations
1. Introduction
7. Market Dynamics
8. Industry Risk Analysis
10. Global Leukemia Therapeutics Market
11. Competitive Structure
Companies Mentioned
- Amgen Inc.
- F. Hoffmann-La Roche Ltd.
- AstraZeneca Plc.
- Novartis AG
- AbbVie Inc.
- Sanofi
- Gilead Sciences
